Abstract
Inflammatory bowel diseases (IBDs) include both Crohn's disease and ulcerative colitis and both diseases are marked by inflammation within the gastrointestinal tract. Due to long-standing inflammation, IBD patients are at increased risk of colorectal cancer, especially patients with chronic inflammation, pancolitis, co-diagnosis of primary sclerosing cholangitis and a longer duration of disease. Small bowel inflammation places Crohn's patients at an increased risk of small bowel cancer. A higher risk of skin cancers, lymphomas and cervical abnormalities is also seen in IBD patients; this is likely related to both disease factors and the presence of immunosuppressive medication. This article reviews which patients are at an increased risk of IBD-associated or IBD treatment-associated cancers, when to begin screening and which screening methods are recommended.
Original language | English (US) |
---|---|
Pages (from-to) | 731-746 |
Number of pages | 16 |
Journal | Expert Review of Gastroenterology and Hepatology |
Volume | 9 |
Issue number | 6 |
DOIs | |
State | Published - Jul 1 2015 |
Keywords
- Biologics
- Crohn's disease
- IBD-associated cancer
- Ulcerative colitis
- colorectal cancer
- inflammatory bowel disease
- lymphoma
- skin cancer
- thiopurines
ASJC Scopus subject areas
- Hepatology
- Gastroenterology